Nautilus Biotechnology (NAUT) Liabilities and Shareholders Equity (2020 - 2026)

Nautilus Biotechnology has disclosed Liabilities and Shareholders Equity across 7 years of filings, most recently posting $177.8 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $177.8 million, down 21.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $783.0 million (down 21.93% YoY), and the FY2025 annual result was $191.1 million, down 21.27% from the prior year.
• Liabilities and Shareholders Equity came in at $177.8 million for Q1 2026 at Nautilus Biotechnology, down from $191.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $384.7 million in Q1 2022 to a low of $177.8 million in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $288.6 million (2024), against an average of $284.8 million.
• Across the five-year window, Liabilities and Shareholders Equity jumped 155.6% in 2022 and retreated 22.64% in 2025, its largest moves.
• Nautilus Biotechnology's Liabilities and Shareholders Equity stood at $350.1 million in 2022, then retreated by 12.71% to $305.6 million in 2023, then declined by 20.56% to $242.7 million in 2024, then fell by 21.27% to $191.1 million in 2025, then fell by 6.98% to $177.8 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $177.8 million (Q1 2026), $191.1 million (Q4 2025), and $200.9 million (Q3 2025), per Business Quant data.